According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 4.30%, which means the company has less short interest than most of its peers. Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why I'm bullish on BMY heading into 2025.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors,

Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong growth prospects and low valuation.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. (Reporting by Sneha S K and Sriparna Roy in Bengaluru;

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an injectable version of the pharmaceutical major’s cancer drug Opdivo. Opdivo is reportedly part of PD-1 inhibitors class of drugs,

The FDA has reportedly approved an injectable formulation of Bristol-Myers Squibb's (NYSE:BMY) oncology drug Opdivo. Previously, the PD-1 inhibitor drug was only available through IV infusion. The injectable formulation,